Showing results (191-200 of 213) with videos related to
Sort By:
Pageof 22
European Journal of Nuclear Medicine and Molecular Imaging|March 1, 2023
89Zr-immuno-PET using the anti-LAG-3 tracer [89Zr]Zr-BI 754111: demonstrating target specific binding in NSCLC and HNSCCIris H C Miedema, Marc C Huisman, Gerben J C Zwezerijnen, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 13, 2021
PD-L1 PET/CT Imaging with Radiolabeled Durvalumab in Patients with Advanced-Stage Non-Small Cell Lung CancerJasper Smit, Frank J Borm, Anna-Larissa N Niemeijer, et al.EJNMMI Research|January 23, 2018
Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibodyYvonne W S Jauw, Marc C Huisman, Tapan K Nayak, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 25, 2024
First-in-Human Evaluation of Site-Specifically Labeled 89Zr-Pertuzumab in Patients with HER2-Positive Breast CancerRandy Yeh, Joseph A O'Donoghue, Vetri Sudar Jayaprakasam, et al.Molecular Imaging and Biology|May 2, 2018
Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical ImagesYvonne W S Jauw, Dennis F Heijtel, Josée M Zijlstra, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 23, 2022
89Zr-Labeled High-Density Lipoprotein Nanoparticle PET Imaging Reveals Tumor Uptake in Patients with Esophageal CancerKang H Zheng, Jeffrey Kroon, Jasper Schoormans, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 25, 2018
PARP-1-Targeted Radiotherapy in Mouse Models of GlioblastomaStephen A Jannetti, Giuseppe Carlucci, Brandon Carney, et al.The Lancet. Oncology|May 31, 2024
Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranosticsAndrew M Scott, Brian M Zeglis, Suzanne E Lapi, et al.Molecular Cancer Therapeutics|June 22, 2016
Bevacizumab Targeting Diffuse Intrinsic Pontine Glioma: Results of 89Zr-Bevacizumab PET Imaging in Brain Tumor ModelsMarc H A Jansen, Tonny Lagerweij, A Charlotte P Sewing, et al.Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 26, 2016
PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancerJudith van Loon, Aniek J G Even, Hugo J W L Aerts, et al.Pageof 22